Dopamine Sensitive ELISA Assay Utilized in Recent Publication

The Eagle Bioscience’s Mouse PD-L1 ELISA Kit was highlighted in a recent publication that explored gene guided OX40L expression on tumor cells to initiate tumor “self-killing”. Check out the full text and abstract below.


The low objective response rates and severe side effects largely limit the clinical outcomes of immune checkpoint blockade (ICB) therapy. Here, a tumor “self-killing” therapy based on gene-guided OX40L anchoring to tumor cell membrane was reported to boost ICB therapy. We developed a highly efficient delivery system HA/PEI-KT (HKT) to co-deliver the OX40L plasmids and unmethylated CG-enriched oligodeoxynucleotide (CpG). On the one hand, CpG induced the expression of OX40 on T cells within tumors. On the other hand, OX40L plasmids achieved the OX40L anchoring on the tumor cell membrane to next promote T cells responses via OX40/OX40L axis. Such synergistic tumor “self-killing” strategy finally turned “cold” tumors to “hot”, to sensitize tumors to programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) blockade therapy, and promoted an immune-mediated tumor regression in both B16F10 and 4T1 tumor models, with prevention of tumor recurrence and metastasis. To avoid the side effects, the gene-guided OX40L anchoring and PD-L1 silencing was proposed to replace the existing antibody therapy, which showed negligible toxicity in vivo. Our work provided a new possibility for tumor “self-killing” immunotherapy to treated various solid tumors.

Lin, Lin, et al. “Gene-Guided OX40L Anchoring to Tumor Cells for Synergetic Tumor ‘Self-Killing’ Immunotherapy.” Bioactive Materials, 2022,

If you have any questions about the Mouse PD-L1 ELISA Kit or our other offerings, please contact us here.